{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["1d8d2c2f-fa5e-420d-a3b4-822ebda287c5", "Q2", 33545, "ROCK & ASSOCIATES", 141938, "VETERINARY PHARMACIES OF AMERICA, INC.", 2013, "second_quarter", "2013-07-15T17:12:02.090000-04:00", 9375.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/1d8d2c2f-fa5e-420d-a3b4-822ebda287c5/\", \"filing_uuid\": \"1d8d2c2f-fa5e-420d-a3b4-822ebda287c5\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2013, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/1d8d2c2f-fa5e-420d-a3b4-822ebda287c5/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"9375.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"James W. Rock, President\", \"dt_posted\": \"2013-07-15T17:12:02.090000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"517 C Street, NE\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20002\", \"registrant\": {\"id\": 33545, \"url\": \"https://lda.senate.gov/api/v1/registrants/33545/\", \"house_registrant_id\": 30422, \"name\": \"ROCK & ASSOCIATES\", \"description\": \"Government relations consultant.\", \"address_1\": \"517 C Street, NE\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20002\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"JAMES W. ROCK\", \"contact_telephone\": \"+1 703-627-8226\", \"dt_updated\": \"2025-02-03T11:57:31.624210-05:00\"}, \"client\": {\"id\": 141938, \"url\": \"https://lda.senate.gov/api/v1/clients/141938/\", \"client_id\": 101, \"name\": \"VETERINARY PHARMACIES OF AMERICA, INC.\", \"general_description\": \"Independently owned retail pharmacy.\", \"client_government_entity\": false, \"client_self_select\": false, \"state\": \"TX\", \"state_display\": \"Texas\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": null, \"ppb_state_display\": null, \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2013-04-16\"}, \"lobbying_activities\": [{\"general_issue_code\": \"MED\", \"general_issue_code_display\": \"Medical/Disease Research/Clinical Labs\", \"description\": \"S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 22837, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"W\", \"last_name\": \"ROCK\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 22837, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"W\", \"last_name\": \"ROCK\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"LAW\", \"general_issue_code_display\": \"Law Enforcement/Crime/Criminal Justice\", \"description\": \"Proposals to amend the Controlled Substances Act to clarify the definition of \\\"dispense\\\" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 22837, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"W\", \"last_name\": \"ROCK\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 22837, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"W\", \"last_name\": \"ROCK\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["1d8d2c2f-fa5e-420d-a3b4-822ebda287c5"], "units": {}, "query_ms": 15.049526002258062, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}